{
    "clinical_study": {
        "@rank": "47039", 
        "arm_group": [
            {
                "arm_group_label": "Condrosulf (Chondroitin 4&6 sulfate)", 
                "arm_group_type": "Experimental", 
                "description": "1 tablet of Condrosulf 800 mg and 1 capsule of placebo of Celebrex once a day for 182 days"
            }, 
            {
                "arm_group_label": "Placebo (PBO) 800 mg tablet and Placebo (PBO) 200 mg capsule", 
                "arm_group_type": "Placebo Comparator", 
                "description": "1 tablet of PBO of Condrosulf and 1 capsule of PBO of Celebrex, once a day for 182 days"
            }, 
            {
                "arm_group_label": "Celebrex 200 mg capsule", 
                "arm_group_type": "Active Comparator", 
                "description": "1 capsule of 200 mg of Celebrex and 1 tablet of 800 mg placebo of Condrosulf once a day for 182 days"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to confirm the efficacy and safety of 800 mg  Chondroitin 4&6\n      sulfate (Condrosulf) vs placebo once a day for 6 months in the symptomatic treatment of knee\n      osteoarthritis. A third group, Celecoxib 200 mg (Celebrex) once a day, will be used as\n      active comparator."
        }, 
        "brief_title": "Condrosulf vs Celebrex vs Placebo in the Treatment of Knee OA", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Knee Osteoarthritis", 
        "condition_browse": {
            "mesh_term": [
                "Osteoarthritis", 
                "Osteoarthritis, Knee"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Outpatients of either sex, aged \u226550 years\n\n          -  Patients affected by primary knee osteoarthritis of the medial or lateral\n             femoro-tibial compartment\n\n          -  Diagnosis  according to the American College of Rheumatology (ACR) criteria\n\n          -  Kellgren & Lawrence grade I-III\n\n          -  Knee osteoarthritis evolving for more than 6 months\n\n          -  Patients suffering from regular pain and functional disorders from at least 3 months\n\n          -  Accomplishing a score \u2265 7 of Lequesne's index for the knee osteoarthritis\n\n          -  Assessing pain on Huskisson's VAS \u2265 50 mm\n\n          -  With radiography dated less than six months showing a remaining articular joint space\n\n          -  Without such an axial disorder to justify an osteotomy\n\n          -  Women taking contraceptive measures if not in menopause\n\n          -  Women having negative pregnancy test\n\n          -  Patients able to understand and follow the study protocol\n\n          -  Patients who have signed the written informed consent for their participation in the\n             clinical trial\n\n        Exclusion Criteria:\n\n          -  Mild or not symptomatic knee osteoarthritis : < 7 of Lequesne's index,\n\n          -  Pain on Huskisson's VAS (Visual Analogic Scale) < 50 mm\n\n          -  Predominantly femoro-patellar osteoarthritis\n\n          -  Destructive osteoarthritis of the knee justifying a surgery in the following 6 months\n\n          -  Osteoarthritis with hydrarthrosis requiring a puncture or an infiltration\n\n          -  Important genu varum or valgus >8\u00b0 (physiological angle including)\n\n          -  Kellgren & Lawrence grade IV\n\n          -  Knee joint surgery in the last 3 months (e.g. chondroscopy, arthroscopy)\n\n          -  Viscosupplementation, tidal lavage in the last 6 months\n\n          -  Arthritis and metabolic arthropathies, Paget's illness\n\n          -  Having consumed: basic treatment of arthritis with SYSADOA, symptomatic slow acting\n             drugs for osteoarthrithis (chondroitin sulphates, glucosamine sulphates, diacerhein,\n             hyaluronic acid and food supplement for joint care) in the last 3 months; treatment\n             with corticoids, by any administration route during the last month; any medication\n             having an influence on pain:\n\n          -  NSAIDs (nonsteroidal anti-inflammatory drugs) in the 5 days preceding the inclusion\n             (wash-out period considering 5 half-lives of the drug)\n\n          -  hypnotics, muscle relaxants, anxiolytics, if the intake has started less than 8 days\n             before inclusion\n\n          -  paracetamol in the 10 hours preceding the inclusion\n\n          -  Foreseen physiotherapy, re-education, alternative medicine (mesotherapy, acupuncture)\n             in the next six months (study period)\n\n          -  Presenting: serious organic diseases as renal or hepatic insufficiency or blood\n             dyscrasia or/and psychiatric illness hindering the protocol compliance, alcoholism,\n             ongoing or < 1 year drug dependency\n\n          -  Patients with a history of heart attack or stroke, or who have experienced chest pain\n             related to heart disease, or who have had serious disease of the heart\n\n          -  Patients with high risk of cardiovascular events\n\n          -  Patients with any acute or chronic infections requiring antimicrobial therapy or\n             serious viral (e.g., hepatitis, HIV positivity) or fungal infections\n\n          -  Patients with a history of recurrent gastrointestinal ulceration or active\n             inflammatory bowel diseases (e.g., Crohn's disease or ulcerative colitis), or a\n             significant coagulation defect\n\n          -  Patients who have been diagnosed as having or have been treated for oesophageal,\n             gastric, pyloric channel, or duodenal ulceration within 30 days prior to receiving\n             the first dose of study medication\n\n          -  Patients presenting lactose intolerance\n\n          -  Pregnant or likely to become it during clinical trial or lactating\n\n          -  Women having positive pregnancy test\n\n          -  Having participated in other clinical trials in the month preceding the clinical\n             trial."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02079727", 
            "org_study_id": "12EU/Ct06", 
            "secondary_id": "2013-001619-62"
        }, 
        "intervention": [
            {
                "arm_group_label": "Condrosulf (Chondroitin 4&6 sulfate)", 
                "intervention_name": "chondroitin sulfate", 
                "intervention_type": "Drug", 
                "other_name": "Condrosulf"
            }, 
            {
                "arm_group_label": "Celebrex 200 mg capsule", 
                "intervention_name": "celecoxib", 
                "intervention_type": "Drug", 
                "other_name": "Celebrex"
            }, 
            {
                "arm_group_label": "Placebo (PBO) 800 mg tablet and Placebo (PBO) 200 mg capsule", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug", 
                "other_name": "placebo for chondroitin sulfate and placebo for celecoxib"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Celecoxib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Condrosulf", 
            "Chondroitin sulfate", 
            "Celebrex", 
            "Knee OA", 
            "Knee osteoarthritis"
        ], 
        "lastchanged_date": "March 4, 2014", 
        "number_of_arms": "3", 
        "official_title": "A Multicentre, Comparative, Randomised, Double-blind, Double-dummy Clinical Trial on the Efficacy and Safety of Condrosulf Versus Celebrex and Versus a Placebo in the Treatment of Knee Osteoarthritis", 
        "other_outcome": {
            "measure": "Treatment compliance", 
            "safety_issue": "No", 
            "time_frame": "Day 1, 30, 91 and 182"
        }, 
        "overall_official": {
            "affiliation": "Unit\u00e9 d'Exploration du M\u00e9tabolisme Osseux, CHU Centre ville, Polycliniques Universitaires L-Brull, Li\u00e8ge, Belgium", 
            "last_name": "Jean-Yves Reginster, Prof. MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Belgium: AFMPS - Agence F\u00e9d\u00e9rales des m\u00e9dicaments et des produits de sant\u00e9", 
                "Czech Republic: SUKL - State Institute for Drug Control", 
                "Italy: The Italian Medicines Agency", 
                "Poland: URPL - The Office for Registration of  Medicinal Products, Medical Devices and Biocidal Products", 
                "Switzerland: Swissmedic - Swiss Agency for Therapeutic Products"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Decrease in the scores of the Lequesne's Index from Day 1 to Day 182.", 
                "measure": "Lequesne's Index", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 182"
            }, 
            {
                "description": "Decrease in the VAS (pain in mm) from Day 1 to Day 182", 
                "measure": "Pain (VAS in mm)", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 182"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02079727"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evolution from Day 1 to Day 30, Day 90 and Day 182", 
                "measure": "Lequesne's Index", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 30, 90 and 182"
            }, 
            {
                "description": "Evolution of the pain on VAS (in mm) from Day 1 to Day 30, Day 91 and Day 182", 
                "measure": "Pain (VAS in mm)", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 30, 91 and 182"
            }, 
            {
                "measure": "MCII (minimal clinically important improvement)", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 30, 91 and 182"
            }, 
            {
                "measure": "PASS (patient acceptable symptom state)", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 30, 91 and 182"
            }, 
            {
                "measure": "Consumption of Paracetamol", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 30, 91 and 182"
            }, 
            {
                "description": "Global efficacy assessed by the patient and the Investigator by means of a semi-quantitative verbal scale.", 
                "measure": "Global efficacy assessment", 
                "safety_issue": "No", 
                "time_frame": "At Day 30, 91 and 182"
            }, 
            {
                "measure": "Number of adverse events related to the treatments", 
                "safety_issue": "Yes", 
                "time_frame": "At Day 30, 91 and 182"
            }, 
            {
                "measure": "Number of drop-outs due to AE (adverse event) related to the treatment", 
                "safety_issue": "Yes", 
                "time_frame": "At Day 30, 91 and 182"
            }
        ], 
        "source": "IBSA Institut Biochimique SA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "IBSA Institut Biochimique SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}